유전자 독성 시험 시장 규모, 점유율, 동향 분석 리포트 : 유형별(인비트로, 인비보), 제품별(시약 및 소모품, 어세이, 서비스), 용도별, 지역별, 부문별 예측(2022-2030년)
Genetic Toxicology Testing Market Size, Share & Trends Analysis Report By Type (In-vitro, In-vivo), By Product (Reagents & Consumables, Assays, Services), By Application, By Region, And Segment Forecasts, 2022 - 2030
유전자 독성 시험 시장의 성장과 동향
Grand View Research, Inc.의 새로운 리포트에 따르면 세계의 유전자 독성 시험 시장 규모는 2030년까지 35억 7000만 달러에 달할 것으로 예측되고 있습니다. 이 시장은 2022-2030년 CAGR 12.7%로 확대할 것으로 예측됩니다. 맞춤형 의약품의 사용량 증가와 세계에서 세포·유전자 치료의 발전이 유전자 독성에 대한 수요를 높이고 있습니다.
목차
제1장 조사 방법
- 시장 세분화와 범위
- 조사 방법
- 정보 조달
- 구입한 데이터베이스
- Gvr의 내부 데이터베이스
- 2차 정보
- 1차 조사
- 1차 조사 상세
- 정보 또는 데이터 분석
- 시장 책정과 검증
- 모델 상세
- 상품 플로우 분석
- 어프로치 1 : 상품 플로우 어프로치
- 어프로치 2 : 보텀업 어프로치를 사용한 국가별 시장 예측
- 세계 시장 : CAGR 계산
- 조사의 가정
- 2차 정보 리스트
- 1차 정보 리스트
- 목적
- 약어 리스트
제2장 시장의 정의
제3장 주요 요약
제4장 세계의 유전자 독성 시험 시장 : 변수, 동향 및 범위
- 유전자 독성 시험 시장 계통 전망
- 침투와 성장 전망 지도제작
- 규제 프레임워크
- 시장 촉진요인 분석
- 세포·유전자 치료의 발전
- 약물유전체학과 맞춤형 의료의 사용 증가
- 새로운 식품 수입의 증가
- 시장 억제요인 분석
- 보험계약에 관한 애매한 규제
- 한정된 정보를 제공하는 능력
- COVID-19 영향 분석
- Porter's Five Forces 분석
- SWOT 분석
제5장 유전자 독성 시험 시장 : 부문 분석, 유형별, 2018-2030년(100만 달러)
- 세계의 유전자 독성 시험 시장 :형 변동 분석
- 인비트로
- 인비보
제6장 유전자 독성 시험 시장 : 부문 분석, 제품별, 2018-2030년(100만 달러)
- 세계의 유전자 독성 시험 시장 : 제품 변동 분석
- 시약과 소모품
- 어세이
- 서비스
제7장 유전자 독성 시험 시장 : 부문 분석, 애플리케이션별, 2018-2030년(100만 달러)
- 유전자 독성 시험 시장 : 애플리케이션 변동 분석
- 제약 및 바이오테크놀러지
- 식품 업계
- 화장품 업계
- 기타
제8장 유전자 독성 시험 시장 : 부문 분석, 지역별, 2018-2030년(100만 달러)
- 유전자 독성 시험 시장 : 지역 변동 분석
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카(MEA)
제9장 경쟁 구도
- 공개 회사
- 회사의 시장 현황 분석
- 경쟁 대시보드 분석
- 전략적 프레임워크
- 비공개 회사
- 주요 신규 기업/테크놀러지 디스럽터/이노베이터 리스트
- 지역 네트워크 맵
- 기업 개요
- Thermo Fisher Scientific, Inc
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
- CHARLES RIVER LABORATORIES INTERNATIONAL
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
- Laboratory Corp of America Holdings
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
- EUROFINS SCIENTIFIC
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
- JUBILANT LIFE SCIENCES LIMITED
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
- SYNGENE INTERNATIONAL LIMITED
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
- GENTRONIX LTD.
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
- INOTIV INC.
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
- CREATIVE BIOARRAY
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
- MB RESEARCH LABORATORIES
- 회사 개요
- 재무 실적
- 제품 벤치마킹
- 전략적 구상
KSA 22.10.17
Genetic Toxicology Testing Market Growth & Trends:
The global genetic toxicology testing market size is expected to reach USD 3.57 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 12.7% from 2022 to 2030. The rising usage of personalized medicines, combined with the development of cell and gene therapy across the globe is enhancing the demand for genotoxicity. For instance, the U.S. FDA has designed guidance documents for the manufacturers of cell and gene therapy. According to the guidance, information on the identification of toxicities and physiologic parameters in preclinical studies can assist in guiding clinical monitoring for the investigational product.
Increasing implementation of pharmacogenomics to support personalized medicine usage and reduced risk of adverse drug toxicity is considered to have a significant impact on the growth of the industry. Moreover, organizations, such as the Dutch Pharmacogenetics Working Group (DPWG), Clinical Pharmacogenetics Implementation Consortium (CPIC), the French National Network of Pharmacogenetics, and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), have issued clinical guidelines with a primary focus on the pharmacogenomics testing interpretation and recommendation on therapeutic specific drug-gene pairs.
Similarly, the market players are indulging in various strategies to expand their footprint in multiple segments. For instance, in November 2021, Labcorp announced the acquisition of Toxikon, a Contract Research Organization (CRO) with offerings in nonclinical testing services. Through this acquisition, Labcorp is anticipated to strengthen its toxicology business and Toxikon's location enables Labcorp to engage with known biotech and pharmaceutical companies in the region for non-clinical work.
The COVID-19 pandemic is anticipated to have a neutral impact on the genetic toxicology testing market growth. Numerous researchers employed genotoxic to assess the effects of drugs against the COVID-19 virus. For instance, in September 2020, a team of researchers evaluated the impact of Chloroquine (CQ) and Hydroxychloroquine (HCQ) as prophylactic drugs against the virus. The genetic toxicology of various drugs and chemicals was assessed. Such studies using genetic toxicology testing as a tool of assessment are anticipated to support stable growth during the peak of COVID-19.
The rising demand for novel food and its imports is expected to be a contributor to market growth. Charles River Laboratories is one of the major players offering toxicology assessments on novel foods. They offer novel food analysis including genotoxicity, which consist of in vivo micronucleus test, Ames study, In Vitro Mammalian Cell Micronucleus, and in the vivo comet assay. Similarly, in January 2021, EFSA published its evaluation of insect-derived food. It is the first kind of assessment conducted by the institution on the insect product as a novel food. Every year, EFSA receives a large number of applications, consisting of herbal products based on algae foods, plants, and non-indigenous fruits.
On the other hand, the ability to retrieve information through genetic toxicology is limited. According to the Pathology Tests Explained organization, genetic tests offer information regarding the specific diseases/gene that is being tested. It does not cover information about other genetic diseases that might be present but have not been tested. Similarly, it cannot identify all the variations of genes that cause the diseases, and also it does not showcase the severity of the diseases. Hence, these limitations are anticipated to hamper the growth of the genetic toxicology industry.
Genetic Toxicology Testing Market Report Highlights:
- By type, the in vitro is expected to be the fastest growing segment with the largest share of the Genetic Toxicology Testing Market in 2021. Owing to the rising requirement by regulatory agencies for genotoxicity in the food industry
- By application, the pharmaceutical & biotechnology segment is estimated to become a major market contributor. This is attributed to an increase in the development of cell and gene therapy, coupled with increasing use of pharmacogenomics and personalized medicines
- The Asia Pacific region is projected to grow substantially over the forecasted period owing to the increasing imports of novel food and tightening test regulations for the same, especially in Australia
- By product, the service segment captured a significant proportion of the share in 2021, owing to the increasing demand by pharmaceutical and biotechnology companies for nonclinical works. Also, increasing strategic initiatives by contract research organizations is a major growth determinant
- North America was a major regional market for genetic toxicology in 2021 owing to the availability of efficient players in the region to match the demand by pharma and biotech companies. The increasing R&D in personalized medicines is also a significant factor
- Some of the main market players include Thermo Fisher Scientific, Inc.; Charles River Laboratories International; Laboratory Corp of America Holdings; and Eurofins Scientific
Table of Contents
Chapter 1 Research Methodology
- 1.1 Market Segmentation & Scope
- 1.1.1 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 Gvr's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details Of Primary Research
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach 1: Commodity flow approach
- 1.6.1.2 Approach 2: Country - wise market estimation using a bottom - up approach
- 1.7 Global Market: CAGR Calculation
- 1.8 Research Assumptions
- 1.9 List of Secondary Sources
- 1.10 List of Primary Sources
- 1.11 Objectives
- 1.11.1 Objective 1:
- 1.11.2 Objective 2:
- 1.12 List Of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
Chapter 4 Global Genetic Toxicology Testing Market Variables, Trends, & Scope
- 4.1 Genetic Toxicology Testing Market Lineage Outlook
- 4.1.1 Parent Market Outlook
- 4.2 Penetration and Growth Prospect Mapping
- 4.3 Regulatory Framework
- 4.4 Market Driver Analysis
- 4.4.1 Development Of Cell And Gene Therapy
- 4.4.2 Increasing Use Of Pharmacogenomics And Personalized Medicines
- 4.4.3 Increasing Imports Of Novel Food
- 4.5 Market Restraint Analysis
- 4.5.1 Vague Regulations On Insurance Policy
- 4.5.2 Ability To Offer Limited Information
- 4.6 COVID - 19 Impact Analysis
- 4.7 Porter's Five Forces Analysis
- 4.8 SWOT Analysis
Chapter 5 Genetic Toxicology Testing Market - Segment Analysis, by type, 2018 - 2030 (USD Million)
- 5.1 Global Genetic Toxicology Testing Market: Type Movement Analysis
- 5.2 In Vitro
- 5.2.1 In Vitro Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 5.3 In Vivo
- 5.3.1 In Vivo Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Genetic Toxicology Testing Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)
- 6.1 Global Genetic Toxicology Testing Market: Product Movement Analysis
- 6.2 Reagents & Consumables
- 6.2.1 Reagents & Consumables Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.3 Assays
- 6.3.1 Assays Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 6.4 Services
- 6.4.1 Services Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Genetic Toxicology Testing Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
- 7.1 Genetic Toxicology Testing Market: Application Movement Analysis
- 7.2 Pharmaceutical & Biotechnology
- 7.2.1 Pharmaceutical & Biotechnology Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.3 Food Industry
- 7.3.1 Food Industry Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.4. Cosmetics Industry
- 7.4.1 Cosmetics Industry Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 7.4. Other
- 7.4.1 Other Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Genetic Toxicology Testing Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)
- 8.1 Genetic Toxicology Testing Market: Regional Movement Analysis
- 8.2 North America
- 8.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.2.2 U.S.
- 8.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.2.3 Canada
- 8.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.3 Europe
- 8.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.3.2 U.K.
- 8.3.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
- 8.3.3. Germany
- 8.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.3.4 Spain
- 8.3.4.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.3.5 France
- 8.3.5.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.3.6 Italy
- 8.3.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
- 8.4 Asia Pacific
- 8.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.4.2 Japan
- 8.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.4.3 China
- 8.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.4.4 India
- 8.4.4.1 India Market Estimates And Forecast, 2018 - 2030
- 8.4.5 South Korea
- 8.4.5.1 South Korea market estimates and forecast, 2018 - 2030
- 8.4.6 Australia
- 8.4.6.1 Australia market estimates and forecast, 2018 - 2030
- 8.5 Latin America
- 8.5.1 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.5.2 Brazil
- 8.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.5.3 Mexico
- 8.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.5.4 Argentina
- 8.5.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6 Middle East & Africa (MEA)
- 8.6.1 Middle East & Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.6.2 South Africa
- 8.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 8.6.3 Saudi Arabia
- 8.6.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.4 UAE
- 8.6.4.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 9 Competitive Landscape
- 9.1 Public Companies
- 9.1.1 Company Market Position Analysis
- 9.1.2 Competitive Dashboard Analysis
- 9.1.3 Strategic Framework
- 9.2 Private Companies
- 9.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
- 9.2.2 Regional Network Map
- 9.4 Company Profiles
- 9.4.1 Thermo Fisher Scientific, Inc
- 9.4.1.1 Company Overview
- 9.4.1.2 Financial Performance
- 9.4.1.3 Product Benchmarking
- 9.4.1.4 Strategic Initiatives
- 9.4.2 CHARLES RIVER LABORATORIES INTERNATIONAL
- 9.4.2.1 Company Overview
- 9.4.2.2 Financial Performance
- 9.4.2.3 Product Benchmarking
- 9.4.2.4 Strategic Initiatives
- 9.4.3 Laboratory Corp of America Holdings
- 9.4.3.1 Company Overview
- 9.4.3.2 Financial Performance
- 9.4.3.3 Product Benchmarking
- 9.4.3.4 Strategic Initiatives
- 9.4.4 EUROFINS SCIENTIFIC
- 9.4.4.1 Company Overview
- 9.4.4.2 Financial Performance
- 9.4.4.3 Product Benchmarking
- 9.4.4.4 Strategic Initiatives
- 9.4.5 JUBILANT LIFE SCIENCES LIMITED
- 9.4.5.1 Company Overview
- 9.4.5.2 Financial Performance
- 9.4.5.3 Product Benchmarking
- 9.4.5.4 Strategic Initiatives
- 9.4.6 SYNGENE INTERNATIONAL LIMITED
- 9.4.6.1 Company Overview
- 9.4.6.2 Financial Performance
- 9.4.6.3 Product Benchmarking
- 9.4.6.4 Strategic Initiatives
- 9.4.7 GENTRONIX LTD.
- 9.4.7.1 Company Overview
- 9.4.7.2 Financial Performance
- 9.4.7.3 Product Benchmarking
- 9.4.7.4 Strategic Initiatives
- 9.4.8 INOTIV INC.
- 9.4.8.1 Company Overview
- 9.4.8.2 Financial Performance
- 9.4.8.3 Product Benchmarking
- 9.4.8.4 Strategic Initiatives
- 9.4.9 CREATIVE BIOARRAY
- 9.4.9.1 Company Overview
- 9.4.9.2 Financial Performance
- 9.4.9.3 Product Benchmarking
- 9.4.9.4 Strategic Initiatives
- 9.4.10 MB RESEARCH LABORATORIES
- 9.4.10.1 Company Overview
- 9.4.10.2 Financial Performance
- 9.4.10.3 Product Benchmarking
- 9.4.10.4 Strategic Initiatives
